Healthcare of Ontario Pension Plan Trust Fund Invests $16.49 Million in Axsome Therapeutics, Inc. $AXSM

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 97,550 shares of the company's stock, valued at approximately $16,488,000. Healthcare of Ontario Pension Plan Trust Fund owned 0.19% of Axsome Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AXSM. Caxton Associates LLP purchased a new stake in shares of Axsome Therapeutics during the 1st quarter worth approximately $729,000. Inceptionr LLC lifted its stake in Axsome Therapeutics by 3.2% in the first quarter. Inceptionr LLC now owns 4,060 shares of the company's stock valued at $686,000 after purchasing an additional 126 shares during the last quarter. Sei Investments Co. grew its holdings in Axsome Therapeutics by 47.2% during the first quarter. Sei Investments Co. now owns 70,064 shares of the company's stock valued at $11,842,000 after purchasing an additional 22,464 shares during the period. Cetera Investment Advisers grew its holdings in Axsome Therapeutics by 10.4% during the first quarter. Cetera Investment Advisers now owns 10,719 shares of the company's stock valued at $1,812,000 after purchasing an additional 1,013 shares during the period. Finally, NewEdge Wealth LLC purchased a new stake in Axsome Therapeutics in the first quarter worth $619,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Nick Pizzie sold 33,000 shares of the business's stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the completion of the transaction, the chief financial officer directly owned 42,867 shares in the company, valued at $10,291,938.03. The trade was a 43.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mark Coleman sold 6,000 shares of the company's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $230.30, for a total transaction of $1,381,800.00. Following the completion of the transaction, the director directly owned 35,140 shares in the company, valued at approximately $8,092,742. The trade was a 14.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 155,852 shares of company stock valued at $37,230,112 in the last three months. Insiders own 20.60% of the company's stock.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $238.37 on Tuesday. The stock's 50-day simple moving average is $239.46 and its 200 day simple moving average is $201.27. The stock has a market capitalization of $12.27 billion, a price-to-earnings ratio of -63.91 and a beta of 0.60. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. Axsome Therapeutics, Inc. has a 52-week low of $96.09 and a 52-week high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The company had revenue of $191.20 million for the quarter, compared to analysts' expectations of $191.10 million. The firm's revenue was up 57.4% on a year-over-year basis. Research analysts forecast that Axsome Therapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Analyst Ratings Changes

AXSM has been the topic of several research reports. HC Wainwright restated a "buy" rating and issued a $290.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, July 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Axsome Therapeutics in a research note on Friday, July 17th. Wells Fargo & Company lifted their price objective on Axsome Therapeutics from $225.00 to $255.00 and gave the stock an "overweight" rating in a report on Tuesday, May 5th. UBS Group boosted their price objective on Axsome Therapeutics from $251.00 to $259.00 and gave the company a "buy" rating in a research note on Friday, April 10th. Finally, Morgan Stanley raised shares of Axsome Therapeutics from a "reduce" rating to an "overweight" rating in a report on Thursday, June 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Axsome Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $261.48.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.